GRAIL, Inc.
GRALNasdaqHealthcare · Services-Medical Laboratories · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | |
|---|---|---|---|
| Revenue | $147.2M | $125.6M | $55.5M |
| Operating income | −$562.2M | −$2.19B | −$5.44B |
| Net income | −$408.4M | −$2.03B | −$5.40B |
| Total assets | $2.92B | $2.98B | $3.91B |
| Total liabilities | $344.2M | $479.9M | $267.6M |
| Equity | $2.58B | $2.50B | — |
| EPS (diluted) | $-11.11 | $-63.54 | $-173.89 |
| Shares out. | 33.9M | 0 | 0 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −382.0%
- Net margin
- −277.5%
- Return on equity
- −15.8%
- Return on assets
- −14.0%
- Return on capital (ROCE)
- −19.8%
- Liabilities / assets
- 11.8%
- Debt / equity
- 0.13×
- Book value / share
- $76.05
- Revenue growth (YoY)
- 17.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -2.86distress
- Accruals / assets
- −3.7%clean
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Baker Bros. Advisors LpPassive (13G)May 15, 2026
- Farallon Capital Partners, L.P.Passive (13G)May 11, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Illumina, Inc.Passive (13G)Feb 17, 2026
- Primecap Management Co/Ca/Passive (13G)Feb 11, 2026
- Crcm LpPassive (13G)Oct 6, 2025
- Blackrock, Inc.Passive (13G)Jul 17, 2025
- Sessa Capital (Master), L.P.Passive (13G)May 7, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Mizell StevenDirector | Apr 15, 2026 | Grant | 396 | $49.79 |
| Chase William JDirector | Apr 15, 2026 | Grant | 408 | $49.79 |
| Summe Gregory LDirector | Apr 15, 2026 | Grant | 631 | $49.79 |
| Freidin AaronOfficer — Chief Financial Officer | Apr 8, 2026 | Sell | 45,806 | $49.92 |
| Ragusa Robert POfficer — Chief Executive Officer | Apr 8, 2026 | Sell | 123,502 | $49.92 |
| Ofman Joshua J.Officer — President | Apr 8, 2026 | Sell | 61,665 | $49.92 |
| Freidin AaronOfficer — Chief Financial Officer | Mar 5, 2026 | Sell | 655 | $53.01 |
| Ofman Joshua J.Officer — President | Mar 5, 2026 | Sell | 690 | $53.01 |
| Ragusa Robert POfficer — Chief Executive Officer | Mar 5, 2026 | Sell | 980 | $53.01 |
| Ofman Joshua J.Officer — President | Feb 27, 2026 | Grant | 84,540 | $53.23 |
| Freidin AaronOfficer — Chief Financial Officer | Feb 27, 2026 | Grant | 60,118 | $53.23 |
| Ragusa Robert POfficer — Chief Executive Officer | Mar 2, 2026 | Sell | 35,787 | $50.09 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 7.2M | 11.4 | +2.4% |
| Apr 30, 2026 | 7.0M | 13.4 | -0.1% |
| Apr 15, 2026 | 7.0M | 7.5 | -2.4% |
| Mar 31, 2026 | 7.2M | 8.7 | +9.6% |
| Mar 13, 2026 | 6.5M | 5.6 | +3.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Other material eventJun 1, 2026
- Results of operationsMay 5, 2026
- Results of operations · Other material eventFeb 19, 2026
- Results of operationsJan 12, 2026
- Other material eventNov 14, 2025
- Results of operationsNov 12, 2025
- Entered a material agreement · Unregistered equity saleOct 20, 2025
- Entered a material agreement · Results of operations · Unregistered equity sale · Regulation FD disclosureOct 16, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spun off from IlluminaILMN · Jun 24, 2024
From the spin-off filings we track. Follow a company to walk its own history.